SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.06500.0%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mimbari who wrote (12132)6/28/2013 4:56:57 PM
From: NTTG1 Recommendation

Recommended By
Pogeu Mahone

  Read Replies (1) of 13111
 
Narrow approval is always understood to be a within disease state description, as in "PV-10 will not be studied further for aggressive stage III or stage IV patients, only non aggressive stage III disease.....hence they will only be able to actively promote drug use for non-aggressive stage III patients" (Actually, this point has been a matter of public record for some time, a bit surprised you reacted to that statement?). This is in marked contrast to other drugs in late stage development, or recently approved, that are looking at both stage III and stage IV disease.

You have confused the companies misnomer about 'broad spectrum' activity for RB...a hold over from Dee's former ID days where antibiotics are described as having 'narrow' or 'broad' spectrum activity depending on their ability to kill Gram positive, Gram negative and/or atypical pathogens.

Simple stuff
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News